Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 68

1.

What are your views on commercialization of tissues for research?

Evers K, Forsberg JS, Eliason JF.

Biopreserv Biobank. 2012 Dec;10(6):476-8. doi: 10.1089/bio.2012.1062. No abstract available.

PMID:
24845132
2.

Covalently immobilized glycosaminoglycans enhance megakaryocyte progenitor expansion and platelet release.

Kishore V, Eliason JF, Matthew HW.

J Biomed Mater Res A. 2011 Mar 15;96(4):682-92. doi: 10.1002/jbm.a.33024. Epub 2011 Jan 25.

3.

Steroid receptor and growth factor receptor expression in human nonsmall cell lung cancers using cells procured by laser-capture microdissection.

Kerr A 2nd, Eliason JF, Wittliff JL.

Adv Exp Med Biol. 2008;617:377-84. doi: 10.1007/978-0-387-69080-3_36.

PMID:
18497061
4.
5.

Transcriptional profiling of degraded RNA in cryopreserved and fixed tissue samples obtained at autopsy.

Haller AC, Kanakapalli D, Walter R, Alhasan S, Eliason JF, Everson RB.

BMC Clin Pathol. 2006 Dec 4;6:9.

6.

Direct detection of herceptin/trastuzumab binding on breast tissue sections.

Glazyrin A, Shen X, Blanc V, Eliason JF.

J Histochem Cytochem. 2007 Jan;55(1):25-33. Epub 2006 Sep 6.

PMID:
16957165
7.

Common EGFR mutations conferring sensitivity to gefitinib in lung adenocarcinoma are not prevalent in human malignant mesothelioma.

Cortese JF, Gowda AL, Wali A, Eliason JF, Pass HI, Everson RB.

Int J Cancer. 2006 Jan 15;118(2):521-2. No abstract available.

9.

Laser Scanning Cytometry for selection of green fluorescent protein transgenic mice using small number of blood cells.

Megyeri A, Kaplan J, Eliason JF.

J Biochem Biophys Methods. 2004 Oct 29;61(1-2):183-7.

PMID:
15560934
10.

Potential for predicting toxicity and response of fluoropyrimidines in patients.

Eliason JF, Megyeri A.

Curr Drug Targets. 2004 May;5(4):383-8. Review.

PMID:
15134221
11.

In vitro and in vivo assays for high-molecular-weight pegylated muteins of granulocyte colony-stimulating factor.

Eliason JF, Tare N, Bowen S, Inoue T, Horii I.

Methods Mol Biol. 2004;249:167-76. No abstract available.

PMID:
14573899
12.

Uridine phosphorylase is a potential prognostic factor in patients with oral squamous cell carcinoma.

Miyashita H, Takebayashi Y, Eliason JF, Fujimori F, Nitta Y, Sato A, Morikawa H, Ohashi A, Motegi K, Fukumoto M, Mori S, Uchida T.

Cancer. 2002 Jun 1;94(11):2959-66.

13.

Expression of uridine and thymidine phosphorylase genes in human breast carcinoma.

Kanzaki A, Takebayashi Y, Bando H, Eliason JF, Watanabe Si S, Miyashita H, Fukumoto M, Toi M, Uchida T.

Int J Cancer. 2002 Feb 10;97(5):631-5.

14.
15.

Pegylated cytokines: potential application in immunotherapy of cancer.

Eliason JF.

BioDrugs. 2001;15(11):705-11. Review.

PMID:
11707145
16.

Random monoallelic expression of three genes clustered within 60 kb of mouse t complex genomic DNA.

Sano Y, Shimada T, Nakashima H, Nicholson RH, Eliason JF, Kocarek TA, Ko MS.

Genome Res. 2001 Nov;11(11):1833-41.

17.

The DNA of annexin V-binding apoptotic cells is highly fragmented.

Bacsó Z, Everson RB, Eliason JF.

Cancer Res. 2000 Aug 15;60(16):4623-8.

18.

Phemx, a novel mouse gene expressed in hematopoietic cells maps to the imprinted cluster on distal chromosome 7.

Nicholson RH, Pantano S, Eliason JF, Galy A, Weiler S, Kaplan J, Hughes MR, Ko MS.

Genomics. 2000 Aug 15;68(1):13-21.

PMID:
10950922
19.

Extended activity in cynomolgus monkeys of a granulocyte colony-stimulating factor mutein conjugated with high molecular weight polyethylene glycol.

Eliason JF, Greway A, Tare N, Inoue T, Bowen S, Dar M, Yamasaki M, Okabe M, Horii I.

Stem Cells. 2000;18(1):40-5.

20.

Relationship between molecular mass and duration of activity of polyethylene glycol conjugated granulocyte colony-stimulating factor mutein.

Bowen S, Tare N, Inoue T, Yamasaki M, Okabe M, Horii I, Eliason JF.

Exp Hematol. 1999 Mar;27(3):425-32.

PMID:
10089904
21.

Inhibition of hepatitis-B-virus core promoter by p53: implications for carcinogenesis in hepatocytes.

Uchida T, Takahashi K, Tatsuno K, Dhingra U, Eliason JF.

Int J Cancer. 1996 Sep 17;67(6):892-7.

22.

Mofarotene (Ro 40-8757) inhibits hematopoiesis in vitro by preventing maturation from primitive progenitor cells.

Eliason JF, Baumgartner M, Yoshikubo T, Hirabayashi Y, Mitsui H, Inoue T.

Blood. 1995 Dec 15;86(12):4516-26.

PMID:
8541541
23.

The dithiane Ro 44-5912 enhances vinblastine sensitivity of drug resistant and parental KB lines in vivo.

Eliason JF, Sawada R, Tsukaguchi T, Kobayashi K, Ichihara S, Konishi C, Horii I, Kuruma I, Ramuz H.

Eur J Cancer. 1995 Dec;31A(13-14):2354-61.

PMID:
8652269
24.

Novel dithiane analogues of tiapamil with high activity to overcome multidrug resistance in vitro.

Eliason JF, Ramuz H, Yoshikubo T, Ishikawa T, Yamamoto T, Tsuruo T.

Biochem Pharmacol. 1995 Jul 17;50(2):187-96.

PMID:
7632162
25.

Purification, cloning, and expression of murine uridine phosphorylase.

Watanabe S, Hino A, Wada K, Eliason JF, Uchida T.

J Biol Chem. 1995 May 19;270(20):12191-6.

26.

Down-regulation of mitochondrial gene expression by the anti-tumor arotinoid mofarotene (Ro 40-8757).

Uchida T, Inagaki N, Furuichi Y, Eliason JF.

Int J Cancer. 1994 Sep 15;58(6):891-7.

PMID:
7927884
27.

The anti-tumor arotinoid Ro 40-8757 protects bone marrow from the toxic effects of 5-fluorouracil.

Eliason JF, Inoue T, Kubota A, Horii I, Hartmann D.

Int J Cancer. 1994 Apr 15;57(2):192-7.

PMID:
8157357
28.

Interferon alpha and 5'-deoxy-5-fluorouridine in colon cancer: effects as single agents and in combination on growth of xenograft tumours.

Laurent PL, Tevaearai HT, Eliason JF, Givel JC, Odartchenko N.

Eur J Cancer. 1994;30A(12):1859-65.

PMID:
7880618
29.

The anti-tumor arotinoid Ro 40-8757 protects bone marrow from the toxic effects of cyclophosphamide.

Eliason JF, Inoue T, Kubota A, Teelmann K, Horii I, Hartmann D.

Int J Cancer. 1993 Sep 30;55(3):492-7.

PMID:
8375933
30.

Anti-proliferative effects of the arotinoid Ro 40-8757 on human cancer cell lines in vitro.

Eliason JF, Kaufmann F, Tanaka T, Tsukaguchi T.

Br J Cancer. 1993 Jun;67(6):1293-8.

31.
32.

Responsiveness of three newly established human colorectal cancer cell lines to transforming growth factors beta 1 and beta 2.

Suardet L, Gaide AC, Calmès JM, Sordat B, Givel JC, Eliason JF, Odartchenko N.

Cancer Res. 1992 Jul 1;52(13):3705-12.

33.

Interactions of interferon-alpha 2a with 5'-deoxy-5-fluorouridine in colorectal cancer cells in vitro.

Tevaearai HT, Laurent PL, Suardet L, Eliason JF, Givel JC, Odartchenko N.

Eur J Cancer. 1992;28(2-3):368-72.

PMID:
1534247
34.
35.

Independent prognostic value of ploidy in colorectal cancer. A prospective study using image cytometry.

Albe X, Vassilakos P, Helfer-Guarnori K, Givel JC, de Quay N, Suardet L, Eliason JF, Odartchenko N.

Cancer. 1990 Sep 15;66(6):1168-75.

PMID:
2400968
36.
37.
38.

Epidermal growth factor responsiveness of a new human neuroblastoma cell line.

Suardet L, Gross N, Gaide AC, Beck D, Eliason JF.

Int J Cancer. 1989 Oct 15;44(4):661-8.

PMID:
2529221
39.

Aggravation of experimental cutaneous leishmaniasis in mice by administration of interleukin 3.

Feng ZY, Louis J, Kindler V, Pedrazzini T, Eliason JF, Behin R, Vassalli P.

Eur J Immunol. 1988 Aug;18(8):1245-51.

PMID:
2970970
40.

[Colorectal cancer: research on new biologic methods of therapeutic and prognostic value].

Givel JC, Matter M, Couson F, Eliason JF, Albe X, Vassilakos P, Odartchenko N.

Helv Chir Acta. 1988 Jun;55(1-2):71-7. French. No abstract available.

PMID:
3215775
41.

The roles of granulocyte-macrophage colony-stimulating factor and interleukin 3 in stromal cell-mediated hemopoiesis in vivo.

Eliason JF, Thorens B, Kindler V, Vassalli P.

Exp Hematol. 1988 May;16(4):307-12.

PMID:
3282901
43.

The EORTC Clonogenic Assay Screening Study Group (CASSG) program.

Aapro MS, Eliason JF, Herman C, Uitendaal M, Rozencweig M.

Prog Clin Biol Res. 1988;276:255-64. No abstract available.

PMID:
3174680
44.

Colony formation in vitro as a prognostic indicator for primary breast cancer.

Aapro MS, Eliason JF, Krauer F, Alberto P.

J Clin Oncol. 1987 Jun;5(6):890-6.

PMID:
3035110
46.

[Comparative prognostic study of the in vitro and in vivo development of colorectal tumors. Preliminary communication].

Givel JC, Matter M, Eliason JF, Odartchenko N.

Schweiz Med Wochenschr. 1986 Jul 19;116(29):964-6. French.

PMID:
3764378
47.

Stimulation of hematopoiesis in vivo by recombinant bacterial murine interleukin 3.

Kindler V, Thorens B, de Kossodo S, Allet B, Eliason JF, Thatcher D, Farber N, Vassalli P.

Proc Natl Acad Sci U S A. 1986 Feb;83(4):1001-5.

48.
49.

Recombinant murine GM-CSF from E. coli has biological activity and is neutralized by a specific antiserum.

DeLamarter JF, Mermod JJ, Liang CM, Eliason JF, Thatcher DR.

EMBO J. 1985 Oct;4(10):2575-81.

50.

Non-linearity of colony formation by human tumour cells from biopsy samples.

Eliason JF, Aapro MS, Decrey D, Brink-Petersen M.

Br J Cancer. 1985 Sep;52(3):311-8.

Supplemental Content

Loading ...
Support Center